Patients with Ph+ ALL are less likely to get CR and exhibit CR rates of approximately 70% to 80%.[33] Our results indicated that the therapy has a stronger effect in the common ALL BCR/ABL+ patients who received TKI than that in the BCR/ABL− patients who display the CD10+ population, while there were no differences in the other populations. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.